The detection of solitary pulmonary nodules (SPNs) that may potentially develop into a malignant lesion is essential for early clinical interventions. However, grading classification based on computed tomography (CT) imaging results remains a significant challenge. The 2-[ 
IntroductIon
The widespread use of chest computed tomography (CT) scanning technology has contributed to significantly increased detection of solitary pulmonary nodules (SPNs). The detection of potentially malignant lesions is critical for early clinical interventions and to increase the survival rate of patients as Phase I patients have a 5-year survival rate of 54-73% after the resection of lung cancer, but for patients with Phase IV, the rate is only 2%.
[1] However, grading classification based on imaging results has remained a significant challenge because of incomplete CT imaging information to allow the differentiation of benign and malignant lesions on size, edge shape, or lesion density. Some studies reported that only 0-1% of SPNs with a diameter <5 mm were malignant, but 33-64% of those 11-20 mm and 64-82% over 20 mm were malignant. An irregular edge and a shape that is lobular or burr shape also suggest the possibility of malignancy. When compared with a solid nodule, the ground-glass or semi-solid nodule has a greater chance of malignancy. [2] The evaluation of pulmonary nodular size and shape and these corresponding risk factors have been widely used to evaluate SPN and to provide guidance for recommended follow-up. [3] Positron emission tomography (PET)/CT was developed to allow qualitative diagnosis of SPN, and it was reported to provide 87% sensitivity and 83% specificity for the detection of a malignant lesion. [3] However, subsequent studies warned of the potential for false-positive and false-negative findings in the diagnosis of SPNs using 2-[ PET/CT and reported that 18 F-FDG PET exhibited low sensitivity to nodules with a diameter of <10 mm, resulting in false-negative findings for lung adenocarcinoma and carcinoid and mucinous adenocarcinomas and false-positive reports due to infectious diseases, tuberculosis, fungal infection, and sarcoidosis. [4, 5] However, one study of 1-and 2-h 18 F-FDG dual-phase imaging suggested that the technique improved the detection rate of malignant lesions of SPNs and showed that the retention index of 18 F-FDG was higher in potentially malignant lesions compared to benign lesions. [6] However, 18 F-FDG is not widely available, stimulating interest in the exploration of alternative materials for use as possible tracers. As an alternative to 18 F-FDG, 3-deoxy-3-[
18 F]-fluorothymidine ( 18 F-FLT) can reveal the ongoing processes of DNA synthesis and cell proliferation. However, application of 18 F-FLT in the diagnosis of lung cancer showed only a sensitivity of 74% to nonsmall cell lung cancer (NSCLC) compared to 94% using 18 F-FDG. [7] A subsequent study also concluded that 18 F-FLT was not as sensitive as 18 F-FDG for the diagnosis of NSCLC with 18 F-FLT showing 72% sensitivity compared to 89% for 18 F-FDG; the standardized uptake value (SUV) was also much lower for 18 F-FLT. [8] However, 18 F-FLT has been widely used to evaluate the curative effects of lung cancer. In contrast to 18 F-FDG, 18 F-FLT imaging was reported to be more sensitive to the treatments of NSCLC, allowing earlier determination of curative efficiency and better evaluation of posttreatment changes in tumor size compared to CT. [9] In addition, researchers have explored the intake differences between 18 F-FLT and 11 C-deoxyglucose (DG) in lung cancer cell using in vitro laboratory experiments. Cytological examination indicated that lung cancer cells incorporated much more 18 
F-FLT than

11
C-DG during the S-phase of the cell division cycle. [10] Thus, it remains important to perform further studies evaluating the uptake and imaging of 18 F-FDG and 18 F-FLT from a standpoint of cytology, using both animal models and clinical patients to determine in more detail the cytological and molecular biological mechanisms of accurate and meaningful imaging. In this work, our first aim was to investigate the uptake difference and estimate the role of the Ki-67 tumor proliferation index in 
Cell culture and probe binding assay
Lung cancer A549 cells were provided by the Institute of General Surgery of General Hospital of PLA. A549 cells were cultured under routine procedures in RPMI-1640 culture medium and the assay was performed as follows: (1) cells were seeded by 1 × 10 5 per well into six-well plate, incubated for 24 h, and removed for observation under an inverted telescope to determine cell shape; (2) 18 F-FDG 37.0 MBq was diluted into PBS and 500 µl diluent was added to small test tubes and placed into well-type γ-counting instrument (FJ-367, State-owned No. 267 Company, Beijing, China) to adjust the count to 80,000-100,000; (3) 500 µl adjusted tracers were added into the 6-well plate and placed in a 5% CO 2 incubator for cell culture; the same amount of tracers were also added to an empty test tube for the blank control and transferred to the well-type γ-counting instrument for cell counting; (4) at 30, 60, 90, 120, 150, and 180 min, the 6-well plate was removed, the supernatant from each well was taken and washed by PBS three times, 0.5 ml trypsin was added and incubated for 3 min, 1 ml DMEM culture medium was added to neutralize the fluid and mixed, and then the cell suspension liquid was transferred to small test tubes and washed by PBS and transferred to the well-type γ-counting instrument for cell counting; the blank control tubes were also counted; (5) after γ-cell counting, 3 to 6 wells were removed for cell counting and the mean count was used. The repetition time was the same as the sample number, and the experiment was repeated six times.
The adjustment of cytological experimental data and indexes included both cell adjustment and radioactive attenuation adjustment. Cell adjustment was realized by cell counting that normalized the cell count to 10 5 . Radioactive attenuation was calculated as the ratio of the experimental count against the count of blank control for the same time. The uptake rate of A549 cell tracer was calculated by the following formula:
18 F-FDG uptake rate per 10 5 cells (%) = Radioactive count of experimental cells/total radioactive count of the blank control × 100%/cell number.
Ki-67 proliferation assay by flow cytometry detection
After incubating for 48 h, A549 cells were digested and centrifuged to remove the cell debris, and then 0.1% Triton X-100 was added for osmotic treatment. A total of 10 6 cells were taken, and 15 µl MIB-1-fluorescent isothiocyanate (FITC) (Ki-67 monoclonal antibody labeled by FITC) was added and incubated in dark for 30 min. The mixture was then centrifuged to remove the cell suspension for flow cytometry detection with a laser wavelength of 488 nm. The experiment was repeated for six times.
Tissue specimens were cut by eye scissors to homogenate and treated by trypsin. Next, normal saline was added and the sample was filtrated by a 200-hole nylon net for the preparation of a single cell suspension. The suspension was then centrifuged to remove cell debris and 0.1% Triton X-100 was added for penetration treating. F-FLT micro-PET imaging (Explore VISTA micro PET/CT, GE Healthcare, Fairfield, USA) were performed.
Micro
Micro-positron emission tomography/computed tomography analysis
The tumor-bearing mice were randomly assigned into one of the two groups (n = 6 animals per group), the 18 F-FDG or the 18 F-FLT group. The mice were anesthetized using 1% chloral hydrate (0.45 mg/g of body weight) and positioned prone on the scanning table.
18
F-FLT or 18 F-FDG was injected through the tail vein at a dose of 370-555 MBq/kg in 0.25 ml of saline. The micro-PET data were acquired for 10 min at the beginning of the tracer injection and lasted about 1 h. Imaging data were derived from the reconstructed sagittal and coronal images after axial scanning in all animal models. Region of interest (ROI) was drawn on the tumor and the chest as background for three consecutive coronal slices representing the maximum tumor uptake, and the tumor-to-nontumor (lung) uptake ratio of ROI was calculated. [11] Positron emission tomography/computed tomography imaging of patients with solitary pulmonary nodule by 2-[
F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[ F]-fluorothymidine
Patients' data and inclusion criteria The inclusion criteria were according to the SPN definition published by Ost et al.: [12] single pulmonary lesion, clear border, diameter of ≤3 cm, surrounded by inflated lung tissues, no pulmonary atelectasis, no enlargement of pulmonary helium, and no pleural invasion.
Using these criteria, a total of 55 cases with SPN detected by chest CT from April 2005 to August 2011 were selected, among which there were 33 males and 22 females, 17-82 years old with an average age of 62 years. Clinical symptoms mainly included irritable cough, and some patients additionally exhibited hemosputum but not purulent sputum or fever. To correct for selection bias, all cases with SPN detected by chest CT were included in the study. The gold standard was based on pathological diagnosis. The study was approved by the Institutional Review Board of the First Affiliated Hospital of the PLA General Hospital. All patients provided written informed consent and consent for publication of individual patient data.
Positron emission tomography/computed tomography analysis Dose of injection tracer: The dose was 555 MBq/kg for both 18 F-FDG and 18 F-FLT. CT was performed as follows: under normal respiration, the patient was scanned from cranial base to pubis symphysis with a tube voltage of 120 kV, tube electric current of 140 mA, collimation of 5.0 mm, slice thickness of 0.75 mm, 0.5 s/r, pitch of 1.25, and scanning time of 20-30 s. The PET was performed with the three-dimensional collection method, and each window level was scanned for 2-3 min for a total of 6-7 window levels. The CT data were used to perform attenuation correction on the PET images. The ordered subset expectation maximization algorithm was applied to reconstruct the image and obtain coronal, transverse, and sagittal images. Next, the ROI was drawn and the maximum SUV (SUV max ) was automatically computed by the processing workstation.
The diagnostic physician observed the systemic distribution of the radioactive tracer to evaluate whether the imaging was successful, and based on the lesion site and the shape and concentration of the tracer, an independent diagnosis was made by three physicians. For the semi-quantitative method, the ROI was drawn within the maximum radioactive concentration area of the transverse image and the SUV max was detected. There is no universally accepted cutoff value of malignant lesion standard of 18 F-FLT SUV, and researchers have developed and recommended different standards. [13, 14] In this study, the cutoff SUV max value of malignant lesion was ≥2.0 for 18 F-FLT and ≥2.5 for 18 F-FDG.
Evaluation parameters of clinical data
Sensitivity, specificity, and accuracy of both tracers in SPN were calculated.
Statistical analysis
The 18 F-FLT A549 cell uptake rates in A549 cells are shown in Figure 1 . These results indicate that 18 F-FLT more accurately reflected the proliferative activity of tumor cells.
Cancer xenograft 2-[ 18 F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[ 18 F]-fluorothymidine micro-positron emission tomography imaging
The micro-PET results of the A549 cancer xenografts (six per group) with the two tracers are shown in Figure 2 . 18 F-FLT PET imaging of tumors was clearer than that using 18 F-FDG. In addition, imaging of tumors with 18 F-FDG PET showed a slightly higher radioactivity concentration than with 18 F-FLT.
Pathological results of lung cancer patients
The pathological diagnosis results were considered as the gold standard. 18 F-FLT PET/CT imaging had negative results, including two patients with bronchioloalveolar carcinoma, two patients with adenocarcinoma (tumor diameter <1.5 cm), and one patient with mucinous adenocarcinoma (for the region with few tumor cells and a large amount of mucous mass revealed by pathological examination, the CT value was lower than 15 Hounsfield units). The mean SUV of nodules of bronchioloalveolar carcinoma and lung adenocarcinoma was lower than those of lung squamous cell carcinoma nodules. Representative images are shown in Figure 4 . Among the 15 examined patients with pulmonary tuberculosis nodules, 11 patients showed different degrees of 18 F-FDG uptake. The mean SUV of tuberculosis was 6.9 ± 3.1 in 11 patients. The SUV max of tuberculosis nodules was ≥2.5 in 9 of the 11 patients. Four patients showed negative results with 18 F-FDG PET/CT imaging.
2-[
Among the 15 examined patients with pulmonary tuberculosis nodules, ten patients showed slight 18 F-FLT uptake. The mean SUV of tuberculosis was 1.6 ± 1.0 in 11 patients. The SUV max of tuberculosis nodules was <2.0 in seven of the ten patients and the SUV max of three patients was ≥2.0. Five patients of 18 F-FLT PET/CT imaging had negative results.
2-[ 18 F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[ 18 F]-fluorothymidine positron emission tomography/ computed tomography imaging of lung inflammatory nodules
Representative images are shown in Figure 5 . The 13 examined patients with lung inflammatory nodules exhibited different patterns of
18
F-FDG and 18 F-FLT uptake. Based on 18 F-FDG imaging, the mean SUV of lung inflammatory nodules was 3.7 ± 2.0. The SUV max of lung inflammatory nodules was lower than 2.5 in 6 of the 13 patients and >1.0 in 3 of the 13 patients. Three patients showed negative results by 18 F-FDG PET/CT imaging. The 18 F-FLT PET/CT imaging was positive in 7 of the 13 patients and negative in 6 of the 13 patients. The mean SUV of lung inflammatory nodules was 1.1 ± 0.8. The SUV max of lung inflammatory nodules was lower than 2.0 in 5 of the 13 patients and ≥2.0 in 2 of the 13 patients. Figure 6 ]. The SUV max of the two tracers was compared in various SPNs, including lung cancer nodules, tuberculosis nodules, inflammatory nodules, and benign nodules; the results indicate that Table 2 ]. For the 18 F-FDG PET/CT imaging, the SUV max of lung cancer nodules was higher than that of the inflammatory nodules and benign lesions (P < 0.05). However, there was no statistical difference between the lung cancer nodules and tuberculosis nodules (P > 0.05). Similarly, the SUV max of tuberculosis nodules was higher than that of the inflammatory nodules and benign lesions (P < 0.05). For the 18 F-FLT PET/CT imaging, the SUV max of lung cancer nodules was higher than of that of other SPNs (P < 0.05).
Ki-67 expression correlated with 2-[
F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[ F]-fluorothymidine mean maximum standardized uptake value in lung cancer histopathological tissue
As shown in Figure 7 , the proliferation index Ki-67 of lung cancer tissue was significantly positively correlated with the
2-[ 18 F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[ 18 F]-fluorothymidine positron emission tomography/ computed tomography imaging of benign solitary pulmonary nodule and lung cancer nodules
The ten examined patients with other benign lung nodules showed a variable pattern of 18 F-FDG uptake. The SUV max of benign lung nodules was lower than 2.5 in three of the ten patients and ≥2.5 in seven of the ten patients. These benign lung nodules showed also a variable pattern of 18 F-FLT uptake. The 18 F-FLT SUV max of lesions was lower than 2.0 in seven of the ten patients and ≥2.0 in three of the ten patients. The diagnosis value of 18 F-FLT and 18 F-FDG for lung cancer lesions was analyzed according to the pathological results [ Table 1 ]. For SPNs <3 cm, the sensitivity, specificity, and accuracy of 18 F-FDG PET/CT for lung cancer diagnosis were 89%, 67%, and 73%, respectively. Moreover, the sensitivity, specificity, and accuracy of 18 F-FLT PET/CT for lung cancer diagnosis were 71%, 79%, and 76%, respectively. Compared with 18 F-FDG PET/CT imaging, 18 F-FLT PET/CT imaging showed lower sensitivity, higher specificity, and slightly higher accuracy for lung cancer diagnosis.
We also separately analyzed the quantitative performance for various SPNs by PET/CT imaging with the two 
dIscussIon
The diagnosis of SPNs remains a challenging goal for modern medical imaging. PET with 18 F-FDG and PET/CT is used to diagnose and monitor the effects of treatment in lung cancer patients. [15] However, 18 F-FDG is not a tumor-specific tracer, and false-positive findings can occur in inflammatory lesions. [16, 17] Research shows that a malignant or benign SPN is often 18 F-FDG intensified; therefore, 18 F-FDG imaging might have a high false-positive rate. [18] For this reason, there is a need to identify new PET tracers for SPN detection. The thymidine analog 18 F-FLT is a stable tumor cell proliferation imaging agent that has been widely used in humans. [19] Imaging of cellular proliferation provides an alternative noninvasive approach for the diagnosis and staging of lung cancer. Buck et al. [20] found that 18 F-FLT uptake correlates better with the proliferation of lung tumors than does the uptake of 18 F-FDG and might be more useful as a selective biomarker for tumor proliferation.
18 F-FLT is a thymine analog and participates in DNA synthesis.
18
F-FLT is catalyzed by the thymidine kinase-1 (TK-1) to form the 18 F-FLT single phosphoric acid that is trapped in cells. TK-1 is a key enzyme in the DNA repair synthesis pathway and has extremely low activity in the resting stage of cell division but significantly higher activity during late G 1 -phase and S-phase. The relationship between the A549 cell division cycle and 18 F-FLT uptake showed a strong positive connection of the tracer uptake ratio of cells with TK-1 activity. When cell division and cell proliferation were markedly inhibited, the cells'
F-FLT uptake ratio was also obviously decreased, and the expression of the TK-1 level was obviously decreased as well. Therefore, the proliferation activities of tumor cell can be assessed by 18 F-FLT uptake level. [21, 22] Ki-67 is a proliferating cell nuclear antigen and a part of the cellular matrix. Similar to TK-1, Ki-67 expression is increased during the G 1 -, S-, G 2 -, and M-phases of cell division, but it is absent in G 0 -phase. [23] The relation between the 18 F-FLT uptake of NSCLC and Ki-67 showed that 18 F-FLT SUV of the lesions is positively correlated with Ki-67 scores. Therefore,
F-FLT may be used to evaluate proliferation in patients with NSCLC.
In this study, we used cytology, animal models, and clinical data to evaluate the efficacy of the two tracers. In the cytological study, we investigated the Our cytological study indicated that 18 F-FDG is more favorable for the detection of lung cancer cells than 18 F-FLT. The two tracers have a different metabolic pathway and reflect a different physiological process, and the differences in the imaging are likely due to differences in the levels of metabolic substrates (glucose and thymine). We observed that the glucose metabolic level was higher than the thymine metabolic level in A549 cells.
The relationship between cells or the tumor tissue proliferation index Ki-67 and tracers' uptake showed a clear difference in SPN qualitative diagnosis. Cytological experimental results showed that the 18 F-FDG uptake rate of A549 cells was higher than the 18 F-FLT uptake rate. The tumor cell proliferation index Ki-67 showed no significant correlation with the 18 F-FDG uptake rate and showed a significantly positive correlation with 18 F-FLT uptake rate. The results showed that the glucose metabolism was higher than the nucleoside metabolism rate in tumor cells.
18 F-FLT probe enables improved evaluation of lung cancer cell proliferation, and our study results are similar to previous reports. [21, 24] Our results of animal imaging showed that the tumor-to-nontumor uptake ratio of 18 F-FDG was higher than that of 18 F-FLT, similar to the cytological experimental results. This indicates that 18 F-FDG is more efficient for the imaging of lung cancer than 18 F-FLT. The tumor pattern detected by imaging with the two tracers was slightly different, and the 18 F-FDG intensity was slightly higher than that of 18 F-FLT. The differences between the two tracer patterns are likely due to the effects of microenvironment, blood circulation, or differences in metabolism or the involved pathways. [11] The clinical trial results agreed with the cytology and animal experimental results. 18 F-FLT showed significant differences in tumor compared to inflammation, tuberculosis, and benign nodules, but showed no significant difference among inflammation, tuberculosis, and benign nodules. Thus, the 18 F-FLT imaging of the tumor lesion showed a relative specificity. 18 F-FDG imaging showed a significant difference between tumor and nonspecific inflammatory nodules but not a significant difference between tumor and tuberculosis nodules. This showed that there was an overlap between benign lesions and malignant lesions with 18 F-FDG imaging. In addition, it suggests that tuberculosis nodules have strong 18 F-FDG uptake characteristics. 18 F-FDG reflects the amount of glucose utilization of live cells. The main energy source in most physiological and pathological processes in the human body is glucose, and phagocytosis activity and chemotaxis during inflammatory reaction can consume energy. Thus, these processes may influence 18 F-FDG uptake.
F-FLT takes part in DNA synthesis, and it is taken up only by rapidly proliferating cells, so the specificity of 18 F-FLT is significantly higher than that of 18 F-FDG. Tumor proliferation, inflammatory activity, and granuloma formation are all associated with DNA synthesis, but the 18 F-FLT concentration corresponding to inflammatory activity or granuloma formation is lower than that of tumor cells. Additional 18 F-FLT PET imaging could be used as a follow-up procedure to improve diagnostic accuracy after 18 F-FDG PET imaging has given a positive result, but it is unable to allow determination of the benign or malignant status of the lesion.
A combination test using both 18 F-FLT and 18 F-FDG PET can improve the sensitivity and specificity for SPN diagnosis. The results presented in this study showed that the false-negative rate of 18 F-FLT PET was higher than that of 18 F-FDG. This difference may be related to the following factors: (1) 18 F-FLT has the thymine 3' end replaced by 18 F. The affinity of 18 F-FLT with the thymine transporter and TK-1 is only 30% of the normal activity with the thymine, and it is unable to be integrated into the DNA. Rasey et al. [22] reported that after coculture with 3 H-thymidine and 3 H-FLT with A549 lung cancer cells for 60 min, 3 H-thymidine into DNA accounted for 90%, but 3 H-FLT was only 0.2%. Mammalian cells produce dNTPs either by de novo synthesis or through the nucleoside salvage pathway. Schwartz et al. [25] observed the DNA synthesis in six kinds of cells and found that in two kinds of cells, there is mainly de novo synthesis of DNA with little contribution from TK-1 activity. (2) The tumor tissue is polyclonal and evolves. During different stages and for tumors of different pathological cell types, the number of cells in the proliferation period varies widely. These factors may affect the high false-negative rate of 18 F-FLT imaging. In addition, 18 F-FDG and 18 F-FLT imaging may have false-negative results due to factors including lesion size, tumor cell density, tumor differentiation, and blood glucose level.
In conclusion, 18 F-FDG is better than 18 F-FLT for the cytological detection of lung cancer cells. However, 18 F-FLT PET imaging is beneficial in the qualitative diagnosis in the small animal xenograft lung cancer model. According to clinical data, compared with 18 F-FDG PET/CT imaging, 18 F-FLT PET/CT imaging showed low sensitivity but high specificity for lung cancer diagnosis. 18 F-FLT PET imaging can distinguish lung cancer from other SPNs. 18 F-FDG PET imaging showed an overlap in the detection of lung cancer and tuberculosis. We speculate that the differences for these two tracers were due to effects of microenvironment or different metabolisms. Overall, our data suggest that a combination test of 18 F-FLT and 18 F-FDG PET can improve diagnostic specificity and accuracy. 
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